BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23455764)

  • 1. MRI for response assessment in metastatic bone disease.
    Lecouvet FE; Larbi A; Pasoglou V; Omoumi P; Tombal B; Michoux N; Malghem J; Lhommel R; Vande Berg BC
    Eur Radiol; 2013 Jul; 23(7):1986-97. PubMed ID: 23455764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
    J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Study Comparing
    Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
    J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective observational study on diagnostic accuracy of whole-body MRI in solid small round cell tumours.
    Kembhavi SA; Rangarajan V; Shah S; Qureshi S; Arora B; Juvekar S; Laskar S; Vora T; Chinnaswamy G; Ramadwar M; Kurkure P
    Clin Radiol; 2014 Sep; 69(9):900-8. PubMed ID: 24863003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group.
    Lecouvet FE; Talbot JN; Messiou C; Bourguet P; Liu Y; de Souza NM;
    Eur J Cancer; 2014 Oct; 50(15):2519-31. PubMed ID: 25139492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body imaging of bone marrow.
    Schmidt GP; Reiser MF; Baur-Melnyk A
    Semin Musculoskelet Radiol; 2009 Jun; 13(2):120-33. PubMed ID: 19455475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer.
    Iagaru A; Minamimoto R
    PET Clin; 2018 Jul; 13(3):383-393. PubMed ID: 30100077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
    Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
    Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body PET/MRI: the effect of bone attenuation during MR-based attenuation correction in oncology imaging.
    Aznar MC; Sersar R; Saabye J; Ladefoged CN; Andersen FL; Rasmussen JH; Löfgren J; Beyer T
    Eur J Radiol; 2014 Jul; 83(7):1177-1183. PubMed ID: 24780817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
    Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.
    Schmidt GP; Schoenberg SO; Schmid R; Stahl R; Tiling R; Becker CR; Reiser MF; Baur-Melnyk A
    Eur Radiol; 2007 Apr; 17(4):939-49. PubMed ID: 16951929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
    Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
    Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single photon emission computed tomography (SPECT) and SPECT/low-dose computerized tomography did not increase sensitivity or specificity compared to planar bone scintigraphy for detection of bone metastases in advanced breast cancer.
    Haraldsen A; Bluhme H; Røhl L; Pedersen EM; Jensen AB; Hansen EB; Nellemann H; Rasmussen F; Morsing A
    Clin Physiol Funct Imaging; 2016 Jan; 36(1):40-6. PubMed ID: 25257661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
    Schraml C; Schwenzer NF; Sperling O; Aschoff P; Lichy MP; Müller M; Brendle C; Werner MK; Claussen CD; Pfannenberg C
    Cancer Imaging; 2013 Mar; 13(1):63-72. PubMed ID: 23466785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.